Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06282510 · ClinicalTrials.gov registry record · Phase 4
Nasal Antisepsis for C. Auris Prevention
A Phase 4 study of Candida Auris Infection and Colonization, Asymptomatic, sponsored by Mary K Hayden.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 120
- Enrollment target
- 3
- Study locations
NCT06282510: Recruiting Phase 4 study of Candida Auris Infection and Colonization, Asymptomatic, sponsored by Mary K Hayden.
NCT06282510 is a Phase 4 study of Candida Auris Infection and Colonization, Asymptomatic that is actively recruiting participants, run by Mary K Hayden. The registered enrollment target is 120 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06282510, a Phase 4 study of Candida Auris Infection and Colonization, Asymptomatic, is actively recruiting participants, sponsored by Mary K Hayden.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 120 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.
Primary Outcome
Culture detection of C. auris from anterior nares on intervention day 5.
Conditions Studied
Interventions
- DRUG Povidone Iodine Topical
Study Locations (3)
Illinois
- Rush University Medical Center - Chicago
- RML Specialty Hospital - Chicago
- RML Specialty Hospital - Hinsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2028-12 |
| Phase | Phase 4 |
What NCT06282510 shows while recruiting
NCT06282510 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Candida Auris Infection appearing as the primary indexed condition, and to 1 intervention - of which Povidone Iodine Topical is the first listed.
NCT06282510 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06282510 about?
NCT06282510 is a clinical study titled "Nasal Antisepsis for C. Auris Prevention". This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.
What is the current status of trial NCT06282510?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 120 participants. The study started on 2024-01-29. Estimated completion is 2028-12.
What conditions does trial NCT06282510 study?
This clinical trial studies the following conditions: Candida Auris Infection, Colonization, Asymptomatic.
What interventions are being tested in trial NCT06282510?
The interventions under investigation include: Povidone Iodine Topical (DRUG).
Who is sponsoring clinical trial NCT06282510?
This trial is sponsored by Mary K Hayden, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06282510 being conducted?
This trial has 3 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06282510's enrollment target sits among peer trials
120 673rd of 2000 higher than 1,290 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI